The global Antibody Drug Conjugates (ADCs) market is expected to reach $XX billion by 2023 from $XX billion in 2017, at a CAGR of XX%. Antibody Drug Conjugates are the novel and emerging class of anti-cancer therapies consisting of empowered monoclonal antibodies (mAbs) designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents. They consist of covalently linked monoclonal antibodies to small molecule drugs that target a specific cancer cell reduce systemic toxicity. They also increase the cell-killing potential of monoclonal antibodies (mAbs) and confer higher tumor selectivity resulting in increased tolerability of the drug. The robust growth in the market may be attributed to the extensive research and development activities in the field of antibody drug conjugates. However, high cost of production of ADCs coupled with the difficult upstream and downstream processing might restrict the growth of the market during given forecast period.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global antibody drug conjugate market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global antibody drug conjugate market.
Major industry players profiled as part of the report are Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Astellas Pharma Inc. and Astellas Pharma Inc. among others.
By Target Antigen
Non Haematologic Malignancies
Middle East and Africa
Key questions answered by the report
What will be the global Antibody Drug Conjugates market size from 2018 to 2023?
How are the major drivers and restraints affecting the global Antibody Drug Conjugates market growth and the opportunities which exist for key vendors?
Which segment and region will drive or lead the market growth and why?
A comprehensive analysis of competitive landscape and key market participants’ behaviour
Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth